Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | MDS/AML germline predisposition syndromes in pediatric patients: GATA2 and SAMD9/9L

Marcin Wlodarski • 5 May 2023
MDS 2023
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes

Marcin Wlodarski, MD, PhD, St Jude Children’s Research Hospital, Memphis, TN, comments on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) germline predisposition syndromes, focusing on the role of GATA2 deficiency and SAMD9/SAMD9L (SAMD9/9L) syndromes in children. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marcin Wlodarski

1:23
Key differences between pediatric and adult MDS
Marcin Wlodarski • 5 May 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals